MSN Settles Bladder Drug Dispute with Astellas for $75 Million

India's MSN Pharmaceuticals Secures US Market Rights for Generic Bladder Drug Myrbetriq

India's MSN Pharmaceuticals has secured US market rights for a generic version of the blockbuster bladder drug Myrbetriq after a revised settlement with Japanese Astellas Pharma. This marks the third Indian firm to settle with Astellas Pharma over Myrbetriq, following agreements with Lupin and Zydus Lifesciences, which featured different structures. Astellas had filed patent infringement cases against the three Indian players.

As part of the amended deal, MSN paid an upfront sum of $75 million and agreed to a prepaid, per-unit licensing fee for all Myrbetriq tablets sold in the United States. The prepaid per-unit licensing fee is a type of royalty to sell or distribute a specific number of units. The deal allows Hyderabad-based MSN to continue commercializing the generic while resolving lingering disputes around formulation and "food-effect" patents, key pillars of Astellas's defence strategy.

Astellas said the financial impact would be reflected in its FY27 guidance, locking in near-term cash flows ahead of the expiry of the patent later in the decade. Mirabegron, a key therapy for overactive bladder, has US sales of around $1 billion.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The MSN amendment is notable not just for the access it grants but also for the benchmark it sets. It follows similar settlements signed earlier this year by Lupin and Zydus Lifesciences, both of which chose to resolve US litigation rather than pursue prolonged appeals. A comparison of the agreements is as follows:

For Lupin and Zydus, these agreements remove legal overhang and allow continued participation in a large US market. However, economically, the MSN deal casts their settlements in a harsher light. It adds competition for the product, once seen as a potential high-margin complex generic. Upfront payments depress near-term cash flows, while continuing per-unit fees cap profitability just as the market matures.

Shares of Zydus Lifesciences declined 2.37 percent and Lupin 2.03 percent to trade at Rs 909.80 and 2277.15, respectively, on BSE at 11 am.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline